Bulletin
Investor Alert

New York Markets Open in:

Protagonist Therapeutics Inc.

NAS: PTGX

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 17, 2022, 7:55 p.m.

/zigman2/quotes/205674595/composite

$

8.61

Change

0.00 0.00%

Volume

Volume 499,211

Quotes are delayed by 20 min

/zigman2/quotes/205674595/composite

Previous close

$ 8.59

$ 8.61

Change

+0.02 +0.23%

Day low

Day high

$8.39

$8.85

Open

52 week low

52 week high

$7.87

$50.54

Open

David Y. Liu

David Y. Liu founded Trenovus, Inc. Currently, he is Chief Scientific Officer, Head-R&D at Protagonist Therapeutics, Inc.

He previously was Chief Operating Officer of Trenovus, Inc., Vice President-Research at FibroGen, Inc., Director-Inflammation Research at Scios, Inc. and Assistant Professor-Medicine Department at Harvard Medical School.

Dr. Liu received a doctorate from Michigan State University and an undergraduate degree from The University of Chicago.

Transactions

Date Shares Transaction Value
02/28/2022 2,119   Derivative/Non-derivative trans. at $24.28 per share. 51,450
02/15/2022 10,000   Award at $0 per share. 0
08/17/2021 14,779   Disposition at $47.56 per share. 702,890
08/17/2021 10,000   Derivative/Non-derivative trans. at $0.87 per share. 8,700
02/26/2021 10,000   Award at $0 per share. 0
08/06/2019 3,395   Disposition at $8.85 per share. 30,046
03/01/2019 810   Disposition at $8.03 per share. 6,505
02/28/2019 15,000   Award at $0 per share. 0
02/06/2019 3,821   Disposition at $7.74 per share. 29,575
08/15/2018 25,800   Award at $0 per share. 0
03/12/2018 3,500   Disposition at $21.29 per share. 74,515
03/12/2018 3,500   Derivative/Non-derivative trans. at $4.21 per share. 14,735
03/02/2018 875   Disposition at $20 per share. 17,500
03/02/2018 875   Derivative/Non-derivative trans. at $1.89 per share. 1,653
02/28/2018 9,500   Award at $0 per share. 0
01/16/2018 875   Disposition at $20 per share. 17,500
01/16/2018 875   Derivative/Non-derivative trans. at $1.89 per share. 1,653
12/18/2017 875   Disposition at $20 per share. 17,500
12/18/2017 875   Derivative/Non-derivative trans. at $1.89 per share. 1,653
11/30/2017 875   Disposition at $20 per share. 17,500
11/30/2017 875   Award at $1.89 per share. 1,653
11/13/2017 3,500   Disposition at $16.97 per share. 59,395
11/13/2017 3,500   Derivative/Non-derivative trans. at $1.89 per share. 6,615
11/13/2017 3,500   Disposition at $16.97 per share. 59,395
11/13/2017 3,500   Derivative/Non-derivative trans. at $4.21 per share. 14,735
08/28/2017 3,500   Disposition at $15 per share. 52,500
08/28/2017 3,500   Derivative/Non-derivative trans. at $4.21 per share. 14,735
07/10/2017 3,500   Disposition at $12.68 per share. 44,380
07/10/2017 3,500   Derivative/Non-derivative trans. at $1.89 per share. 6,615

Officers and Executives

Dr. Dinesh V. Patel
President, Chief Executive Officer & Director
Mr. Asif Ali
Chief Financial Officer & Executive Vice President
Dr. Paula O’Connor
Senior Vice President-Clinical Development
Dr. Mohammad Masjedizadeh
Chief Technical officer & Executive VP
Dr. Mark L. Smythe
Vice President-Technology
Dr. David Y. Liu
Chief Research & Development Strategy Officer
Dr. Samuel R. Saks
Chief Medical Officer
Ms. Tracy M. Woody
Executive Vice President-Commercial Strategy
Dr. Scott Plevy
Executive Vice President & Head-Gastroenterology
Mr. Jami Taylor
Vice President-Corporate Affairs
Dr. Ashok Bhandari
Senior Director-Chemistry
Mr. Carter J. King
Vice President-Business Development
Dr. Suneel Gupta
Chief Development Officer
Ms. Carena Spivey
Executive Director-Human Resources
Mr. Matthew M. Gosling
Executive Vice President & General Counsel
Dr. Harold E. Selick
Chairman
Ms. Sarah A. O'Dowd
Independent Director
Mr. William D. Waddill
Independent Director
Dr. Lewis T. Williams
Independent Director
Dr. Sarah B. Noonberg
Independent Director
Mr. Bryan Giraudo
Independent Director
Link to MarketWatch's Slice.